A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19

Summary

This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.

Conditions

• SARS Coronavirus (SARS-CoV-2) Infection

Interventions

OTHER

Study A

Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.

OTHER

Study B

Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.

OTHER

Study C

Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.

OTHER

Study D

Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment: 1. Lopinavir/Ritonavir 2. Hydroxychloroquine 3. Tocilizumab 4. Eculizumab 5. Ruxolitinib 6. Remdesivir 7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting).

Sponsors & Collaborators

• sciCORE University of Basel

  collaborator UNKNOWN

• Leonhard Med IT ETH Zurich

  collaborator UNKNOWN

• Swiss Institute of Bioinformatics

  collaborator UNKNOWN

• University Hospital, Basel, Switzerland

  lead OTHER

Principal Investigators

• Adrian Egli, Prof. Dr. med. · Division of Clinical Bacteriology & Mycology, University Hospital Basel

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-04-09

Primary Completion

2022-07-31

Completion

2022-07-31

Countries

• Switzerland

Study Locations